Heart failure and tachycardiomyopathy in a patient taking ibrutinib: a novel tyrosine kinase inhibitor.

被引：0

作者：

Codina, M. ^{[1
]}

Ramirez-Escudero, G. ^{[2
]}

Garcia Ibarrondo, N. ^{[2
]}

Manzanal Rey, A. ^{[2
]}

Bravo Martinez, I. ^{[3
]}

Aurrekoetxea Bajeneta, G. ^{[3
]}

Mendoza Cuartero, P. ^{[3
]}

Asla Ormaza, C. ^{[3
]}

Castellano Alcalde, M. ^{[3
]}

Uriarte Elguezabal, J. A. ^{[4
]}

Marquez Navarro, J. A. ^{[4
]}

De Bourio Uriarte, R. Martinez ^{[5
]}

Arregui Lopez, A. ^{[6
]}

Arcocha Torres, M. F. ^{[7
]}

Ruiz Gomez, L. ^{[2
]}

机构：

[1] Hosp Basurto, Noninvas Cardiac Imaging Lab, Cardiooncol, Bilbao, Spain

[2] Hosp Basurto, Noninvas Cardiac Imaging Lab, Bilbao, Spain

[3] Hosp Basurto, Dept Cardiol, Bilbao, Spain

[4] Hosp Basurto, Dept Hematol, Bilbao, Spain

[5] Hosp Basurto, Cardiac Catheterizat Lab, Bilbao, Spain

[6] Hosp Basurto, Cardiol Intens Care Unit, Bilbao, Spain

[7] Hosp Basurto, Dept Cardiol, Electrophysiol Lab, Bilbao, Spain

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P1210

引用

页码：303 / 303

页数：1

共 50 条

[21] Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
Blay, Jean-Yves
von Mehren, Margaret
SEMINARS IN ONCOLOGY, 2011, 38 (02) : S3 - S9
[22] Lapatinib: a novel dual tyrosine kinase inhibitor
Chowdhury, Simon
Pickering, Lisa M.
Ellis, Paul A.
TARGETED ONCOLOGY, 2007, 2 (02) : 106 - 112
[23] Pazopanib: A novel multitargeted tyrosine kinase inhibitor
Sonpavde G.
Hutson T.E.
Current Oncology Reports, 2007, 9 (2) : 115 - 119
[24] Discovery of indazolylpyrimidine GW786034 as a potent pan VEGFR tyrosine kinase inhibitor.
Cheung, M
Baloor, A
Chamberlain, SD
Hinkle, KW
Davis-Ward, RG
Harris, PA
Laudeman, CP
Mook, RA
Nailor, KE
Szewczyk, GR
Veal, JM
McGuire, MA
Truesdale, AT
Johnson, JH
Crosby, RM
Knick, VB
Rudolph, SK
Epperly, AH
Kumar, R
Mullin, RJ
Gilmer, TM
Luttrell, DK
Stafford, JA
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9109S - 9109S
[25] Treatment of canine mast cell tumors with a tyrosine kinase inhibitor. Regarding a clinical case
Machicote, G.
Cobian, A.
Diaz-Santiago, F.
CLINICA VETERINARIA DE PEQUENOS ANIMALES, 2011, 31 (01): : 19 - 27
[26] Inhibition of human plasmacytoma cell growth by a novel JAK kinase inhibitor.
Burger, R
Legouill, S
Tai, YT
Shringarpure, R
Podar, K
Catley, L
Tassone, P
Neri, P
Hideshima, T
Chauhan, D
Fridman, JS
Anderson, KC
BLOOD, 2004, 104 (11) : 186A - 186A
[27] Regression of heart failure in a patient with tachycardiomyopathy secondary to inappropriate sinus tachycardia treated with ivabradine
Salcedo, N.
Jose, A.
Gonzalez, Q.
Dario, G.
Granada, V.
Arenas, Karen S.
Andres, J.
Roncancio, G.
Rincon, Efrain M.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2010, 12 (0A) : S18 - S19
[28] Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib and Interaction With Direct Oral Anticoagulant
Khalid, Muhammad
Khattak, Furqan
Ramu, Vijay
AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (06) : E768 - E769
[29] The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
Castellani, Francesca
Visentin, Andrea
Campagnolo, Marta
Salvalaggio, Alessandro
Cacciavillani, Mario
Candiotto, Cinzia
Bertorelle, Roberta
Trentin, Livio
Briani, Chiara
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04):
[30] Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias
Fabbro, Stephanie K.
Smith, Sabrina M.
Dubovsky, Jason A.
Gru, Alejandro A.
Jones, Jeffrey A.
JAMA ONCOLOGY, 2015, 1 (05) : 684 - 686

← 1 2 3 4 5 →